|
[1]
|
Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet 2013;382(9895):889 − 99. http://dx.doi.org/10.1016/S0140-6736(13)60022-7CrossRef
|
|
[2]
|
de Sanjose S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11(11):1048 − 56. http://dx.doi.org/10.1016/S1470-2045(10)70230-8CrossRef
|
|
[3]
|
Brisson M, Drolet M. Global elimination of cervical cancer as a public health problem. Lancet Oncol 2019;20(3):319 − 21. http://dx.doi.org/10.1016/S1470-2045(19)30072-5CrossRef
|
|
[4]
|
Chen W, Zhang X, Molijn A, Jenkins D, Shi JF, Quint W, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control 2009;20(9):1705 − 13. http://dx.doi.org/10.1007/s10552-009-9422-zCrossRef
|
|
[5]
|
Bao HL, Bi H, Zhang XS, Zhao Y, Dong Y, Luo XP, et al. Artificial intelligence-assisted cytology for detection of cervical intraepithelial neoplasia or invasive cancer: a multicenter, clinical-based, observational study. Gynecol Oncol 2020;159(1):171 − 8. http://dx.doi.org/10.1016/j.ygyno.2020.07.099CrossRef
|
|
[6]
|
Passmore JAS, Morroni C, Shapiro S, Williamson AL, Hoffman M. Papanicolaou smears and cervical inflammatory cytokine responses. J Inflamm 2007;4:8. http://dx.doi.org/10.1186/1476-9255-4-8CrossRef
|
|
[7]
|
Ronco G, Franceschi S, Segnan N. HPV16 and HPV18 genotyping in cervical cancer screening. Lancet Oncol 2011;12(9):831 − 2. http://dx.doi.org/10.1016/S1470-2045(11)70195-4CrossRef
|
|
[8]
|
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2020;8(2):e191 − 203. http://dx.doi.org/10.1016/S2214-109X(19)30482-6CrossRef
|
|
[9]
|
Bao HL, Jin C, Wang S, Song Y, Xu ZY, Yan XJ, et al. Prevalence of cervicovaginal human papillomavirus infection and genotypes in the pre-vaccine era in China: a nationwide population-based study. J Infect 2021;82(4):75 − 83. http://dx.doi.org/10.1016/j.jinf.2021.02.017CrossRef
|
|
[10]
|
Zhao FH, Lewkowitz AK, Hu SY, Chen F, Li LY, Zhang QM, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer 2012;131(12):2929 − 38. http://dx.doi.org/10.1002/ijc.27571CrossRef
|
|
[11]
|
Petry KU, Cox JT, Johnson K, Quint W, Ridder R, Sideri M, et al. Evaluating HPV-negative CIN2+ in the ATHENA trial. Int J Cancer 2016;138(12):2932 − 9. http://dx.doi.org/10.1002/ijc.30032CrossRef
|
|
[12]
|
Reich O, Regauer S, Kashofer K. Possibly carcinogenic HPV subtypes are a cause of HSIL and negative clinical HPV tests - A European prospective single center study. Gynecol Oncol 2020;158(1):112 − 6. http://dx.doi.org/10.1016/j.ygyno.2020.04.685CrossRef
|